Last reviewed · How we verify

Spikevax bivalent Original/Omicron BA.1 — Competitive Intelligence Brief

Spikevax bivalent Original/Omicron BA.1 (Spikevax bivalent Original/Omicron BA.1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mRNA vaccine. Area: Immunology / Infectious Disease.

marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant) Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Spikevax bivalent Original/Omicron BA.1 (Spikevax bivalent Original/Omicron BA.1) — Jules Bordet Institute. This bivalent mRNA vaccine encodes spike proteins from both the original SARS-CoV-2 strain and the Omicron BA.1 variant to elicit immune responses against multiple viral variants.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Spikevax bivalent Original/Omicron BA.1 TARGET Spikevax bivalent Original/Omicron BA.1 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
mRNA-1283 mRNA-1283 ModernaTX, Inc. marketed mRNA vaccine HPV16 and HPV18 antigens (E6 and E7 proteins)
Comirnaty Original/Omicron BA.1 Comirnaty Original/Omicron BA.1 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (original strain and Omicron BA.1 variant)
mRNA-1273 vaccine mRNA-1273 vaccine University Health Network, Toronto marketed mRNA vaccine SARS-CoV-2 spike protein
Spikevax Omicron XBB.1.5 Spikevax Omicron XBB.1.5 Jules Bordet Institute marketed mRNA vaccine SARS-CoV-2 spike protein (XBB.1.5 variant)
COMIRNATY - BioNTech Manufacturing GmbH COMIRNATY - BioNTech Manufacturing GmbH Jens D Lundgren, MD marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)
BioNTech - Pfizer COVID-19 vaccine BioNTech - Pfizer COVID-19 vaccine University of Birmingham marketed mRNA vaccine SARS-CoV-2 spike protein (S protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mRNA vaccine class)

  1. Pfizer · 12 drugs in this class
  2. ModernaTX, Inc. · 11 drugs in this class
  3. BioNTech SE · 5 drugs in this class
  4. Jules Bordet Institute · 5 drugs in this class
  5. Tan Tock Seng Hospital · 2 drugs in this class
  6. Clover Biopharmaceuticals AUS Pty · 1 drug in this class
  7. CanSino Biologics Inc. · 1 drug in this class
  8. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  9. CSPC Megalith Biopharmaceutical Co.,Ltd. · 1 drug in this class
  10. Jens D Lundgren, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Spikevax bivalent Original/Omicron BA.1 — Competitive Intelligence Brief. https://druglandscape.com/ci/spikevax-bivalent-original-omicron-ba-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: